158 related articles for article (PubMed ID: 35033838)
21. Antibody response elicited by the SARS-CoV-2 vaccine booster in patients with multiple sclerosis: Who gains from it?
Schiavetti I; Inglese M; Frau J; Signoriello E; Caleri F; Stromillo ML; Ferrò MT; Rilla MT; Gandoglia I; Gazzola P; Brichetto G; Pasquali L; Grimaldi L; Ulivelli M; Marinelli F; Cordera S; Clerico M; Conte A; Salvetti M; Battaglia MA; Franciotta D; Uccelli A; Sormani MP;
Eur J Neurol; 2023 Aug; 30(8):2357-2364. PubMed ID: 37154406
[TBL] [Abstract][Full Text] [Related]
22. Long term persistence of SARS-CoV-2 humoral response in multiple sclerosis subjects.
Maniscalco GT; Ferrara AL; Liotti A; Manzo V; Di Battista ME; Salvatore S; Graziano D; Viola A; Amato G; Moreggia O; Di Giulio Cesare D; Alfieri G; Di Iorio W; Della Rocca G; Andreone V; De Rosa V
Mult Scler Relat Disord; 2022 Jun; 62():103800. PubMed ID: 35462168
[TBL] [Abstract][Full Text] [Related]
23. Antibody response to SARS-CoV-2 vaccination or infection in a prospective cohort of children with neuroinflammatory diseases.
Kaufmann C; Morris M; Gombolay GY
Eur J Paediatr Neurol; 2023 Sep; 46():30-34. PubMed ID: 37399703
[TBL] [Abstract][Full Text] [Related]
24. [The Second Shot of CoronaVac Vaccine May Cause Reduction of Antibody Levels in People who Previously had COVID-19].
Topkaya AE; Keskin AÜ; Dalan AB; Çıragil P
Mikrobiyol Bul; 2022 Jan; 56(1):139-142. PubMed ID: 35088968
[TBL] [Abstract][Full Text] [Related]
25. Antibody response to SARS-CoV-2 vaccination following typical and three-dose dosing schedules in multiple sclerosis patients treated with disease modifying therapies.
Wallach AI; Schiebel M; Picone MA
Mult Scler Relat Disord; 2022 Jul; 63():103856. PubMed ID: 35636275
[TBL] [Abstract][Full Text] [Related]
26. Safety of disease-modifying treatments in SARS-CoV-2 antibody-positive multiple sclerosis patients.
Mallucci G; Zito A; Baldanti F; Gastaldi M; Fabbro BD; Franciotta D; Bergamaschi R
Mult Scler Relat Disord; 2021 Apr; 49():102754. PubMed ID: 33609958
[TBL] [Abstract][Full Text] [Related]
27. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
Front Immunol; 2021; 12():796482. PubMed ID: 35111162
[TBL] [Abstract][Full Text] [Related]
28. Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis.
Tallantyre EC; Scurr MJ; Vickaryous N; Richards A; Anderson V; Baker D; Chance R; Evangelou N; George K; Giovannoni G; Harding KE; Hibbert A; Ingram G; Jolles S; Jones M; Kang AS; Loveless S; Moat SJ; Robertson NP; Rios F; Schmierer K; Willis M; Godkin A; Dobson R
Mult Scler Relat Disord; 2022 Aug; 64():103937. PubMed ID: 35700625
[TBL] [Abstract][Full Text] [Related]
29. CD19+ B cell values predict the increase of anti-SARS CoV2 antibodies in fingolimod-treated and COVID-19-vaccinated patients with multiple sclerosis.
Schiavetti I; Barcellini L; Lapucci C; Tazza F; Cellerino M; Capello E; Franciotta D; Inglese M; Sormani MP; Uccelli A; Laroni A
Mult Scler Relat Disord; 2023 Feb; 70():104494. PubMed ID: 36603292
[TBL] [Abstract][Full Text] [Related]
30. Impact of Disease-Modifying Treatments of Multiple Sclerosis on Anti-SARS-CoV-2 Antibodies: An Observational Study.
Bigaut K; Kremer L; Fabacher T; Lanotte L; Fleury MC; Collongues N; de Seze J
Neurol Neuroimmunol Neuroinflamm; 2021 Sep; 8(5):. PubMed ID: 34321333
[TBL] [Abstract][Full Text] [Related]
31. The humoral response to SARS-COV-2 vaccines in MS patients: A case series exploring the impact of DMT, lymphocyte count, immunoglobulins, and vaccine type.
Jakubecz C; Zhang XS; Woodson S; Serra A; Abboud H
Mult Scler Relat Disord; 2022 May; 61():103785. PubMed ID: 35381535
[TBL] [Abstract][Full Text] [Related]
32. Cross-sectional analysis of the humoral response after SARS-CoV-2 vaccination in Sardinian multiple sclerosis patients, a follow-up study.
Idda ML; Pitzalis M; Lodde V; Loizedda A; Frau J; Lobina M; Zoledziewska M; Virdis F; Delogu G; Marini MG; Mingoia M; Masala M; Lorefice L; Fronza M; Carmagnini D; Carta E; Pilotto S; Castiglia P; Chessa P; Uzzau S; Farina G; Solla P; Steri M; Devoto M; Fiorillo E; Floris M; Zarbo RI; Cocco E; Cucca F
Front Immunol; 2022; 13():946356. PubMed ID: 36059537
[TBL] [Abstract][Full Text] [Related]
33. [Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study].
Özgür D; Tütüncü EE
Mikrobiyol Bul; 2022 Jan; 56(1):36-48. PubMed ID: 35088958
[TBL] [Abstract][Full Text] [Related]
34. The impact of sphingosine-1-phosphate receptor modulators on COVID-19 and SARS-CoV-2 vaccination.
Baker D; Forte E; Pryce G; Kang AS; James LK; Giovannoni G; Schmierer K
Mult Scler Relat Disord; 2023 Jan; 69():104425. PubMed ID: 36470168
[TBL] [Abstract][Full Text] [Related]
35. Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies.
Fernández J; Bruneau N; Fasce R; Martín HS; Balanda M; Bustos P; Ulloa S; Mora J; Ramírez E
J Med Virol; 2022 Jan; 94(1):399-403. PubMed ID: 34460119
[TBL] [Abstract][Full Text] [Related]
36. Antibody response with SARS-CoV-2 inactivated vaccine (CoronaVac) in Turkish geriatric population.
Okyar Baş A; Hafizoğlu M; Akbiyik F; Güner Oytun M; Şahiner Z; Ceylan S; Ünsal P; Doğu BB; Cankurtaran M; Çakir B; Ünal S; Halil MG
Age Ageing; 2022 May; 51(5):. PubMed ID: 35524745
[TBL] [Abstract][Full Text] [Related]
37. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
38. B-cell depleters attenuate the humoral response to SARS-CoV-2 vaccines in multiple sclerosis patients: A case-control study.
Conte WL
Mult Scler Relat Disord; 2022 Jan; 57():103413. PubMed ID: 35158480
[TBL] [Abstract][Full Text] [Related]
39. SARS-CoV-2 specific antibody responses after third CoronaVac or BNT162b2 vaccine following two-dose CoronaVac vaccine regimen.
Keskin AU; Bolukcu S; Ciragil P; Topkaya AE
J Med Virol; 2022 Jan; 94(1):39-41. PubMed ID: 34536028
[No Abstract] [Full Text] [Related]
40. The Mucosal and Serological Immune Responses to the Novel Coronavirus (SARS-CoV-2) Vaccines.
Chan RWY; Liu S; Cheung JY; Tsun JGS; Chan KC; Chan KYY; Fung GPG; Li AM; Lam HS
Front Immunol; 2021; 12():744887. PubMed ID: 34712232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
